Tuberculosis vaccine - GlaxoSmithKline

Drug Profile

Tuberculosis vaccine - GlaxoSmithKline

Alternative Names: TB vaccine - GlaxoSmithKline

Latest Information Update: 13 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antituberculars; Recombinant fusion proteins; Tuberculosis vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Tuberculosis

Most Recent Events

  • 16 Jan 2004 Phase-I clinical trials in Tuberculosis in USA (unspecified route)
  • 30 Jul 2002 A vaccine candidate has been selected for phase I clinical trials.
  • 28 Sep 2001 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top